William Blair analyst Sami Corwin has maintained their bullish stance on NGNE stock, giving a Buy rating on November 10.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sami Corwin has given his Buy rating due to a combination of factors that highlight Neurogene’s promising prospects. The recent updates from the Phase I/II trial of NGN-401 demonstrate significant and lasting clinical benefits for Rett syndrome patients, regardless of their age or initial condition. This gene therapy, which utilizes Neurogene’s advanced EXACT technology, has shown that patients continue to develop complex skills up to 24 months post-treatment, indicating its potential to be a leading therapy in its class.
Furthermore, the data significantly de-risks the ongoing Embolden registrational trial, as a substantial majority of patients are meeting the necessary criteria for success. Neurogene’s strategic advantages, such as its START designation and efficient enrollment capabilities, position it well to advance the study swiftly. With sufficient funding secured through early 2028 and a potential approval timeline for NGN-401 set for mid- to late 2027, Neurogene is ahead of its competitors, further justifying the Buy rating.
Corwin covers the Healthcare sector, focusing on stocks such as uniQure, Cabaletta Bio, and Solid Biosciences. According to TipRanks, Corwin has an average return of 25.7% and a 54.82% success rate on recommended stocks.
In another report released on November 10, H.C. Wainwright also reiterated a Buy rating on the stock with a $65.00 price target.